http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
-
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
-
Corbus Pharmaceuticals Provides Management Team Updates
-
Corbus Pharmaceuticals Provides Management Team Updates
-
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
-
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
-
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
-
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
-
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
-
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
-
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
-
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
-
Corbus Pharma (CRBP) Enters Strategic Collaboration with Kaken with $27M Upfront Payment
-
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
-
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
-
Corbus Pharma (CRBP) Announces Issuance of Composition of Matter Patent Related to Lenabasum
-
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
-
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
-
Corbus Pharma (CRBP) Commences 'DETERMINE' Phase 3 Study in Dermatomyositis
-
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
-
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
-
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
-
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
-
Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
-
Corbus Pharma (CRBP) Reports Lenabasum Long-Term Open-Label Clinical Data in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
-
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosi
-
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosi
-
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
-
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
-
Corbus Pharma (CRBP) Announces Patent Issuance Covering Use of Lenabasum
-
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
-
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
-
Corbus Pharma (CRBP) Secures Exclusive Global Rights for Over 600 Endocannabinoid System-Related Compounds from Jerin Discovery
-
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 St
-
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 St
-
Corbus Pharma (CRBP) Granted EU Orphan Designation for Lenabasum
-
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
-
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
-
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
-
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
-
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
-
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
-
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
-
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
-
Corbus Pharma (CRBP) Initiates Phase 3 Study of Lenabasum for Treatment of Rare Autoimmune Disease Dermatomyositis
